利索-全球专利检索

  1. 登录
  2. 注册

搜索结果

20 条记录 (耗时 0.053 秒)

    Toxin peptide therapeutic agents
    5.
    发明授权
    Toxin peptide therapeutic agents 有权
    毒素肽治疗剂

    公开(公告)号：US07833979B2

    公开(公告)日：2010-11-16

    申请号：US11406454

    申请日：2006-04-17

    申请人： John K. Sullivan ,  Joseph G. McGivern ,  Leslie P. Miranda ,  Hung Q. Nguyen ,  Kenneth W. Walker ,  Shaw-Fen Sylvia Hu ,  Colin V. Gegg ,  Stefan I. McDonough

    发明人： John K. Sullivan ,  Joseph G. McGivern ,  Leslie P. Miranda ,  Hung Q. Nguyen ,  Kenneth W. Walker ,  Shaw-Fen Sylvia Hu ,  Colin V. Gegg ,  Stefan I. McDonough

    IPC分类号： A61K38/00 ,  C07K14/00

    CPC分类号： A61K47/48215 ,  A61K38/00 ,  A61K47/60 ,  C07K14/43504 ,  C07K2319/30 ,  C07K2319/55

    摘要： Disclosed is a composition of matter of the formula (X1)a—(F1)d—(X2)b—(F2)e—(X3)c  (I) and multimers thereof, in which F1 and F2 are half-life extending moieties, and d and e are each independently 0 or 1, provided that at least one of d and e is 1; X1, X2, and X3 are each independently -(L)f-P-(L)g-, and f and g are each independently 0 or 1; P is a toxin peptide of no more than about 80 amino acid residues in length, comprising at least two intrapeptide disulfide bonds; L is an optional linker; and a, b, and c are each independently 0 or 1, provided that at least one of a, b and c is 1. Linkage to the half-life extending moiety or moieties increases the in vivo half-life of the toxin peptide, which otherwise would be quickly degraded. A pharmaceutical composition comprises the composition and a pharmaceutically acceptable carrier. Also disclosed are a DNA encoding the inventive composition of matter, an expression vector comprising the DNA, and a host cell comprising the expression vector. Methods of treating an autoimmune disorder, such as, but not limited to, multiple sclerosis, type 1 diabetes, psoriasis, inflammatory bowel disease, contact-mediated dermatitis, rheumatoid arthritis, psoriatic arthritis, asthma, allergy, restinosis, systemic sclerosis, fibrosis, scleroderma, glomerulonephritis, Sjogren syndrome, inflammatory bone resorption, transplant rejection, graft-versus-host disease, and lupus and of preventing or mitigating a relapse of a symptom of multiple sclerosis are also disclosed.

    摘要翻译： 公开了式（X1）a-（F1）d-（X2）b-（F2）e-（X3）c（Ⅰ）及其多元素的物质组成，其中F1和F2是半衰期延长 部分，d和e各自独立地为0或1，条件是d和e中的至少一个为1; X1，X2和X3各自独立地为 - （L）f-P-（L）g-，f和g各自独立地为0或1; P是长度不超过约80个氨基酸残基的毒素肽，其包含至少两个肽内二硫键; L是可选的接头; 并且a，b和c各自独立地为0或1，条件是a，b和c中的至少一个为1.与半衰期延长部分或部分的连接增加毒素肽的体内半衰期， 否则会很快退化。 药物组合物包含该组合物和药学上可接受的载体。 还公开了编码本发明组合物的DNA，包含DNA的表达载体和包含表达载体的宿主细胞。 治疗自身免疫性疾病，例如但不限于多发性硬化，1型糖尿病，牛皮癣，炎性肠病，接触介导性皮炎，类风湿性关节炎，银屑病关节炎，哮喘，过敏，再狭窄，系统性硬化，纤维化， 还公开了硬皮病，肾小球肾炎，干燥综合征，炎性骨吸收，移植排斥反应，移植物抗宿主病和狼疮以及预防或减轻多发性硬化症状的复发。

    Methods of using OSK1 peptide analogs
    10.
    发明申请
    Methods of using OSK1 peptide analogs 有权
    使用OSK1肽类似物的方法

    公开(公告)号：US20090318341A1

    公开(公告)日：2009-12-24

    申请号：US11978119

    申请日：2007-10-25

    申请人： John K. Sullivan ,  Joseph G. McGivern ,  Leslie P. Miranda

    发明人： John K. Sullivan ,  Joseph G. McGivern ,  Leslie P. Miranda

    IPC分类号： A61K38/16 ,  A61P37/00 ,  A61P29/00

    CPC分类号： C07K14/43522 ,  A61K38/00 ,  A61K47/60 ,  C07K2319/30 ,  C07K2319/31

    摘要： Disclosed is a composition of matter comprising an OSK1 peptide analog, and in some embodiments, a pharmaceutically acceptable salt thereof. A pharmaceutical composition comprises the composition and a pharmaceutically acceptable carrier. Also disclosed are DNAs encoding the inventive composition of matter, an expression vector comprising the DNA, and host cells comprising the expression vector. Methods of treating an autoimmune disorder and of preventing or mitigating a relapse of a symptom of multiple sclerosis are also disclosed.

    摘要翻译： 公开了包含OSK1肽类似物的物质组合物，并且在一些实施方案中为其药学上可接受的盐。 药物组合物包含该组合物和药学上可接受的载体。 还公开了编码本发明组合物的DNA，包含DNA的表达载体和包含表达载体的宿主细胞。 还公开了治疗自身免疫性疾病和预防或减轻多发性硬化症状的复发的方法。